Abliva (ABLI.ST) Stock Analysis & AI Equity Report
Abliva (ABLI.ST) overview
Abliva (ABLI.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Abliva reported revenue of SEK 0m and operating profit of SEK 0m; the year-end share price was 0.42 SEK and market capitalisation was N/A. Abliva is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Abliva's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About Abliva
Abliva AB is a Swedish biotechnology company developing medicines for primary mitochondrial disease, a rare condition caused by impaired cellular energy production. Its portfolio includes clinical and earlier-stage programs, led by KL1333 and NV354, and the company is focused on advancing therapies for severe orphan diseases. Since July 2025, it has been a wholly owned subsidiary of Pharming Group N.V.
Generate the Abliva report
Abliva is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Abliva and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.